K221077 is an FDA 510(k) clearance for the Auryon Atherectomy System. Classified as Catheter, Peripheral, Atherectomy (product code MCW), Class II - Special Controls.
Submitted by Eximo Medical, Ltd. (Rehovot, IL). The FDA issued a Cleared decision on June 9, 2022 after a review of 58 days - a notably fast clearance cycle.
This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.4875 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.
View all Eximo Medical, Ltd. devices
NCT02556255
Completed
Interventional
Industry-sponsored
Safety and Effectiveness Study of Eximo's B-Laser™ Atherectomy Device for PAD Treatment
Safety and Effectiveness Evaluation of Eximo's B-Laser™ Atherectomy Device, in Subjects Affected With PAD
| Condition studied |
Peripheral Arterial Disease |
| Study design |
Single group |
| Eligibility |
All sexes
· 18 Years+
|
| Principal investigator |
Oshrat Cohen, Ph.D., MBA |
| Sponsor |
Eximo Medical Ltd.
(industry)
|
Started 2015-10-01
→
Primary completion 2017-08-01
→
Completed 2020-11-20
Primary outcome
Number of Participants With 30 Day Freedom From Major Adverse Events
Secondary outcome
Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (2)
View full study on ClinicalTrials.gov